Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers

Journal of Clinical and Aesthetic Dermatology

Volumn 7, Issue 4, 2014, Pages 35-42

  Dosik, Jonathan S ^a   Damstra, Maureen ^a   Udell, Carol ^a   Welburn, Peter ^b  

^a TKL RESEARCH INC   (United States)

^b Q Pharm Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INGENOL MEBUTATE;

ADULT; AGED; APPLICATION SITE IRRITATION; ARTICLE; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EROSION; ERYTHEMA; FEMALE; GEL; GINGIVA DISEASE; HUMAN; MALE; MOUTH ABSCESS; NORMAL HUMAN; PATCH TEST; PHASE 1 CLINICAL TRIAL; PHOTOALLERGY; PHOTOIRRITATION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN DEFECT; SKIN IRRITATION; SKIN SENSITIZATION; TREATMENT RESPONSE; ULTRAVIOLET IRRADIATION;

EID: 84899073823     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Goldberg LH, Mamelak AJ. Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol. 2010;9: 1125-1132.
2. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-230. (Pubitemid 46098882)
3. Fenske NA, Spencer J, Adam F. Actinic keratoses: past, present and future. J Drugs Dermatol. 2010;9(5 Suppl ODAC Conf Pt 1):s45-s49.
4. Hensen P, Müller ML, Haschemi R, et al. Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol. 2009;19:345-354.
5. Berman B, Amini S, Valins W, Block S. Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother. 2009;10:3015-3031.
6. Bonerandi JJ, Beauvillain C, Caquant L, et al. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol. 2011;25(Suppl 5):1-51.
7. Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:39-44.
8. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115:2523-2530.
9. Picato® [package insert]. LEO Pharma; 2012.
10. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177:8123-8132. (Pubitemid 44846331)
11. Hampson P, Chahal H, Khanim F, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood. 2005;106:1362-1368. (Pubitemid 41129602)
12. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64:2833-2839. (Pubitemid 38500622)
13. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66:486-493.
14. Kedei N, Lundberg DJ, Toth A, et al. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004;64:3243-3255. (Pubitemid 38581429)
15. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010-1019.
16. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68(1 Suppl 1):S39-S48.
17. Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head. J Am Acad Dermatol. 2010;62(3 Suppl 1):AB105.
18. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934-943.
19. Ortonne JP, Queille-Roussel C, Duteil L. 3% diclofenac in 2.5% hyaluronic acid (Solaraze™) does not induce photosensitivity or phototoxicity alone or in combination with sunscreens. Eur J Dermatol. 2006;16:385-390. (Pubitemid 44328979)
20. Kaidbey K, Owens M, Liberda M, Smith M. Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. Toxicology. 2002;178:175-182. (Pubitemid 34876808)
21. Miolo G, Marzano C, Gandin V et al. Photoreactivity of 5-fluorouracil under UVB light: photolysis and cytotoxicity studies. Chem Res Toxicol. 2011;24:1319-1326.